Lanthanum Carbonate | 587-26-8

• 物质功能分类: 无机化工 - 无机盐 - 碳化物及碳酸盐
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: Lanthanum Carbonate
• 英文别名: lanthanum(3+);tricarbonate
• CAS: 587-26-8
• 化学式: C3La2O9
• 分子量: 457.84
• InChiKey: NZPIUJUFIFZSPW-UHFFFAOYSA-H

物化性质

• 密度：
  3.48[at 20℃]
• 物理描述：
  DryPowder; OtherSolid
• 颜色/状态：
  White powder
• 溶解度：
  Practically insoluble.

计算性质

• 辛醇/水分配系数(LogP)：
  -7.34
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  190
• 氢给体数：
  0
• 氢受体数：
  9

ADMET

代谢

镧不参与代谢。

Lanthanum is not metabolized.

来源:DrugBank

代谢

镧不会被代谢，也不是CYP450的底物。体外代谢抑制研究表明，在10和40微克/毫升的浓度下，镧对测试的任何CYP450同工酶（1A2、2C9/10、2C19、2D6和3A4/5）均没有相关的抑制作用。

Lanthanum is not metabolized and is not a substrate of CYP450. In vitro metabolic inhibition studies showed that lanthanum at concentrations of 10 and 40 ug/mL does not have relevant inhibitory effects on any of the CYP450 isoenzymes tested (1A2, 2C9/10, 2C19, 2D6, and 3A4/5).

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 药物性肝损伤

碳酸镧

Compound:lanthanum carbonate

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

DILI 注释：无 DILI（药物性肝损伤）担忧

DILI Annotation:No-DILI-Concern

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

标签部分：无匹配

Label Section:No match

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

参考文献：M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. 美国食品药品监督管理局批准的药物标签用于研究药物诱导的肝损伤，《药物发现今日》，16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank：按人类发展药物诱导肝损伤风险排名的最大参考药物清单。《药物发现今日》2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015

References:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 在妊娠和哺乳期间的影响

哺乳期使用概述：目前没有关于人类哺乳期间使用碳酸镧的信息。在动物研究中，镧在幼年动物的骨骼中沉积。碳酸镧不应在哺乳期母亲中使用。建议使用另一种药物。 对哺乳婴儿的影响：截至修订日期，没有找到相关已发表信息。 对泌乳和母乳的影响：截至修订日期，没有找到相关已发表信息。

◉ Summary of Use during Lactation:No information is available on the use of lanthanum carbonate during breastfeeding in humans. In animal studies, lanthanum was deposited in the bones of juvenile animals. Lanthanum carbonate should not be used in nursing mothers. An alternate drug is recommended. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

吸收、分配和排泄

• 吸收

单次或多次口服给药后，生物利用度非常低（<0.002%）。

Bioavailability very low (<0.002%) following single or multiple dose oral administration.

来源:DrugBank

吸收、分配和排泄

• 消除途径

关于人类口服给药后镧的质量平衡，目前没有可用的信息。在大鼠和狗中，口服给药后镧的平均回收率分别约为99%和94%，并且几乎全部来自粪便。在大鼠中，胆汁排泄是循环中镧的主要消除途径。

No information is available regarding the mass balance of lanthanum in humans after oral administration. In rats and dogs, the mean recovery of lanthanum after an oral dose was about 99% and 94%, respectively, and was essentially all from feces. Biliary excretion is the predominant route of elimination for circulating lanthanum in rats.

来源:DrugBank

吸收、分配和排泄

• 清除

在健康的志愿者中，给予静脉注射的氯化镧（120微克）作为可溶性盐，其肾清除率低于总血浆清除率的2%。

In healthy volunteers administered intravenous lanthanum as the soluble chloride salt (120 μg), renal clearance was less than 2% of total plasma clearance.

来源:DrugBank

吸收、分配和排泄

钕在口服给药后从胃肠道最少被吸收；生物利用度小于0.002%。在接受钕治疗剂量的患者中，平均血浆药物浓度保持较低（即，1.1 ng/mL或更少）。

Lanthanum is minimally absorbed from the GI tract following oral administration; bioavailability is less than 0.002%. In patients receiving therapeutic dosages of lanthanum for up to 2 years, mean plasma concentrations of the drug remained low (ie, 1.1 ng/mL or less).

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

在健康受试者单次或多次口服碳酸镧后，血浆中镧的浓度非常低。在终末期肾病患者口服给药后，镧的平均Cmax为1.0 ng/mL。在终末期肾病患者的长期给药（52周）期间，血浆中镧的平均浓度约为0.6 ng/mL。在治疗剂量范围内，随着剂量的增加，血浆中镧的浓度仅有少量增加。尚未评估食物对碳酸镧生物利用度的影响，但食物摄入与镧给药的相对时间（进食期间和进食后30分钟内）对镧的系统性水平几乎没有影响。

Following single or multiple dose oral administration of lanthanum carbonate to healthy subjects, the concentration of lanthanum in plasma was very low. Following oral administration in ESRD patients, the mean lanthanum Cmax was 1.0 ng/mL. During long-term administration (52 weeks) in ESRD patients, the mean lanthanum concentration in plasma was approximately 0.6 ng/mL. There was minimal increase in plasma lanthanum concentrations with increasing doses within the therapeutic dose range. The effect of food on the bioavailability of lanthanum carbonate has not been evaluated, but the timing of food intake relative to lanthanum administration (during and 30 minutes after food intake) has a negligible effect on the systemic level of lanthanum

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 海关编码：
  2846904100

反应信息

• 作为反应物：
  描述：

  Lanthanum Carbonate 、 四氟化硫 生成 氟化镧
  参考文献：
  名称：

  SHENDRIK V. P.; LYAX O. D., ODES. POLITEXN. IN-T, ODESSA,(1987) 4 S., IL., UKRNIINTI , 815-YK87

  摘要：

  DOI：
• 作为产物：
  描述：

  magnesium;hydrogen carbonate 、 氯化镧 反应 2.0h， 生成 Lanthanum Carbonate
  参考文献：
  名称：

  METHOD OF PRECIPITATION OF METAL IONS

  摘要：

  本发明涉及一种金属离子沉淀的方法。采用镁和/或钙的矿物、氧化物、羟基物作为原材料，并通过至少一步煅烧、消石灰或碳化的处理将原材料处理成镁重碳酸盐和/或钙重碳酸盐的水溶液，然后将该溶液用作沉淀剂，沉淀稀土，如镍、钴、铁、铝、镓、铟、锰、镉、锆、铪、锶、钡、铜和锌离子。获得至少一种金属碳酸盐、羟化物或碱式碳酸盐，或者进一步将获得的产品煅烧以产生金属氧化物。本发明采用价格便宜、纯度低的钙和/或镁矿物或其氧化物、羟基物代替常见的沉淀剂，如碳酸铵和碳酸钠等。钙、镁、二氧化碳等被高效循环利用，避免了铵氮废水、高浓度盐类废水对环境的污染，减少了温室气体二氧化碳的排放和金属生产成本。

  公开号：

  US20110280778A1

文献信息

• Storage-stable solutions of accelerator systems
  申请人：Ciba-Geigy Corporation

  公开号：US05470896A1

  公开（公告）日：1995-11-28

  Solutions of accelerator systems comprising a binary system comprising a) 10 to 90% by weight of a salt of formula I [Me].sub.m.sup.x.sym. [R].sub.n.sup.y.crclbar. (I), wherein x and y are the respective number of charges and m and n are each a number 1, 2, 3 or 4, Me is a metal atom and R is the radical of an alcohol, phenol or thiophenol or of a carboxylic acid or thiocarboxylic acid, or 10 to 90% by weight of a salt of formula II [Me.sub.1 ].sub.m.sup.x.sym. [A].sub.n.sup.y.crclbar. (II), with an organic complex former containing one or more hetero atoms having free electron pairs, wherein Me.sub.1 is a metal atom or a group of the formula N(R.sub.1).sub.4, S(R.sub.1).sub.3 or P(R.sub.1).sub.4 wherein each R.sub.1 independently of the others is hydrogen, an unsubstituted or substituted C.sub.1 -C.sub.6 alkyl or aryl radical, A is any anion and x, y, m and n are as defined above, and b) 90 to 10% by weight of an organic solvent containing at least one --OH, --OR.sub.1, --COOH, --COOR.sub.1, --COR.sub.1 or --CON(R.sub.1).sub.2 group wherein R.sub.1 is hydrogen, an unsubstituted or substituted C.sub.1 -C.sub.6 alkyl or aryl radical, are storage-stable with respect to temperature and time and do not precipitate, and the use thereof, for example for accelerating the hardening of epoxy resin/amine combinations, the drying times being in the range of about 15 to 40 minutes.

  加速器系统的解决方案包括二元体系，其中包括a）重量占10％至90％的公式I [Me] .sub.m.sup.x.sym. [R] .sub.n.sup.y.crclbar.（I）的盐，其中x和y分别是电荷数，m和n是1、2、3或4的数字，Me是金属原子，R是醇，酚或硫酚或羧酸或硫代羧酸的基团，或重量占10％至90％的公式II [Me.sub.1] .sub.m.sup.x.sym. [A] .sub.n.sup.y.crclbar.（II）的盐，与含有一个或多个具有自由电子对的杂原子的有机络合剂，其中Me.sub.1是金属原子或公式N（R.sub.1）.sub.4，S（R.sub.1）.sub.3或P（R.sub.1）.sub.4的基团，其中每个R.sub.1独立于其他人是氢，未取代或取代的C.sub.1-C.sub.6烷基或芳基基团，A是任何阴离子，x，y，m和n如上所定义，b）重量占90％至10％的有机溶剂，其中至少含有一个-OH，-OR.sub.1，-COOH，-COOR.sub.1，-COR.sub.1或-CON（R.sub.1）.sub.2基团，其中R.sub.1是氢，未取代或取代的C.sub.1-C.sub.6烷基或芳基基团，对于温度和时间具有储存稳定性且不沉淀，其用途，例如用于加速环氧树脂/胺组合物的固化，干燥时间在约15至40分钟之间。
• Method for the preparation of a rare earth oxide powder
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US05439656A1

  公开（公告）日：1995-08-08

  An improved method is proposed for the preparation of a powder of a rare earth oxide having good dispersibility containing no agglomerates of particles even without undertaking disintegration indispensable heretofore. The improved method comprises precipitation of a rare earth carbonate by the admixture of an aqueous solution of an inorganic rare earth salt with an aqueous solution of ammonium hydrogen carbonate in an excess amount over the stoichiometrically equivalent amount to give a slurry of the rare earth carbonate which is subjected to heating treatment in two steps each under specified conditions to effect aging of the carbonate precipitates. Characteristically, the aqueous slurry after the first aging treatment is subjected to an adjustment in three differently specified ways prior to the second aging treatment including, first, admixture of an additional amount of ammonium hydrogen carbonate, second, addition of water to decrease the solid content in the slurry and, third, addition of an inorganic acid to decrease the pH of the slurry.

  提出了一种改进方法，用于制备具有良好分散性的稀土氧化物粉末，即使不进行以前必不可少的分散处理，也不含颗粒团聚物。改进方法包括通过将无机稀土盐的水溶液与碳酸氢铵的水溶液混合，使稀土碳酸盐沉淀，超过化学计量当量的量，以得到稀土碳酸盐浆，然后在两个特定条件下进行两步加热处理，以使碳酸盐沉淀物老化。特别是，在第一次老化处理后，水浆在第二次老化处理之前以三种不同的方式进行调整，包括：第一，加入额外的碳酸氢铵；第二，加入水以减少水浆中的固体含量；第三，加入无机酸以降低水浆的pH值。
• Method for inhibiting perspiration
  申请人：——

  公开号：US04219540A1

  公开（公告）日：1980-08-26

  Method of inhibiting perspiration with antiperspirant compositions containing trivalent metal salts of trifluoromethanesulfonic acid of the formula: Me (CF.sub.3 SO.sub.3).sub.3 wherein Me is aluminum, lanthanum, cerium or didymium obtained by reacting trifluoromethanesulfonic acid with the appropriate metal carbonate or sulfide or by the exchange reaction of the appropriate metal sulfate with barium trifluoromethanesulfonate.

  使用含有三氟甲磺酸三价金属盐的抗汗剂组合物来抑制汗液的方法，其中该三价金属盐的化学式为：Me（CF3SO3）3，其中Me为铝、镧、铈或镝，该组合物可通过将三氟甲磺酸与适当的金属碳酸盐或硫化物反应或通过适当的金属硫酸盐与三氟甲磺酸钡进行交换反应来获得。
• METHOD OF PRECIPITATION OF METAL IONS
  申请人：Huang Xiaowei

  公开号：US20110280778A1

  公开（公告）日：2011-11-17

  The present invention relates to a method of precipitation of metal ions. Mineral(s), oxide(s), hydroxide(s) of magnesium and/or calcium are adopted as raw materials, and the raw material(s) is processed through at least one step of calcination, slaking, or carbonization to produce aqueous solution(s) of magnesium bicarbonate and/or calcium bicarbonate, and then the solution(s) is used as precipitant(s) to deposit rare earth, such as nickel, cobalt, iron, aluminum, gallium, indium, manganese, cadmium, zirconium, hafnium, strontium, barium, copper and zinc ions. And at least one of metal carbonates, hydroxides or basic carbonates is obtained, or furthermore the obtained products are calcined to produce metal oxides. The invention takes the cheap calcium and/or magnesium minerals or their oxides, hydroxides with low purity as raw materials to instead common precipitants such as ammonium bicarbonate and sodium carbonate etc. The calcium, magnesium, carbon dioxide etc are efficiently and circularly used, and the environment pollution by ammonium-nitrogen wastewater, high concentration salts wastewater is avoided, and both of the discharge of greenhouse gas carbon dioxide and the production cost of metal are decreased.

  本发明涉及一种金属离子沉淀的方法。采用镁和/或钙的矿物、氧化物、羟基物作为原材料，并通过至少一步煅烧、消石灰或碳化的处理将原材料处理成镁重碳酸盐和/或钙重碳酸盐的水溶液，然后将该溶液用作沉淀剂，沉淀稀土，如镍、钴、铁、铝、镓、铟、锰、镉、锆、铪、锶、钡、铜和锌离子。获得至少一种金属碳酸盐、羟化物或碱式碳酸盐，或者进一步将获得的产品煅烧以产生金属氧化物。本发明采用价格便宜、纯度低的钙和/或镁矿物或其氧化物、羟基物代替常见的沉淀剂，如碳酸铵和碳酸钠等。钙、镁、二氧化碳等被高效循环利用，避免了铵氮废水、高浓度盐类废水对环境的污染，减少了温室气体二氧化碳的排放和金属生产成本。
• SHENDRIK V. P.; LYAX O. D., ODES. POLITEXN. IN-T, ODESSA,(1987) 4 S., IL., UKRNIINTI , 815-YK87
  作者：SHENDRIK V. P.、 LYAX O. D.

  DOI：——

  日期：——

表征谱图